This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 40/4/528    most recent 01.HYP.0000033223.17484.B1v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maniu, C. V. Articles by Redfield, M. M. Search for Related Content PubMed PubMed Citation Articles by Maniu, C. V. Articles by Redfield, M. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections Cardio-renal physiology/pathophysiology Other hypertension Autonomic, reflex, and neurohumoral control of circulation ACE/Angiotension receptors Hypertension - basic studies

(Hypertension. 2002;40:528.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Hemodynamic and Humoral Effects of Vasopeptidase Inhibition in Canine Hypertension

From the Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn.

Correspondence to Dr Margaret M. Redfield, Mayo Clinic and Foundation, Cardiorenal Laboratory, Guggenheim 9, 200 First St, SW, Rochester, MN 55905. E-mail redfield.margaret{at}mayo.edu

Vasopeptidase inhibitors are potent new antihypertensive agents. The dual inhibition of ACE and neutral endopeptidase may result in synergistic humoral effects with unique hemodynamic actions. We investigated the hemodynamic and neurohumoral effects of vasopeptidase inhibition in conscious dogs made hypertensive by bilateral renal wrapping and subsequently instrumented for long-term assessment of left ventricular pressure and volume (n=8). Intravenous vasopeptidase inhibition (omapatrilat, 30 µmol/kg over 10 minutes) reduced peak left ventricular pressure (171±6 versus 130±6 mm Hg immediately after infusion, P<0.01) through arterial vasodilation (arterial elastance, 9.8±0.8 to 5.8±1.6 mm Hg/mL, P<0.01) and preload reduction (left ventricular end-diastolic volume, 51.1±6.8 to 46.0±6.9 mL, P<0.01). At 60 minutes, preload decreased further (40.5±5.9 mL, P<0.01 versus baseline). Vasopeptidase inhibition increased plasma levels of adrenomedullin (41.2±9.6 versus 72.3±15 pg/mL, P<0.01), whereas levels of the natriuretic peptides and cGMP were unchanged. Similar hemodynamic and humoral effects were observed with long-term therapy. Neither an equimolar dose of an ACE inhibitor (fosinopril) nor exogenous adrenomedullin had as potent of a hypotensive effect, and neither reduced preload. In summary, the potent short-term and long-term hypotensive effects of vasopeptidase inhibition were prominently mediated by preload reduction, an effect not reproduced by ACE inhibition nor adrenomedullin augmentation and not associated with enhanced natriuretic peptide levels. Combined arterial vasodilation and preload reduction may confer additional potency as well as unique cardioprotective effects. Synergistic effects on humoral and probably endothelial vasodilatory factors appear to be important in mediating the unique hemodynamic profile of vasopeptidase inhibition in this form of experimental hypertension.

Key Words: hypertension, experimental • hemodynamics • natriuretic peptides • angiotensin • drug therapy

This article has been cited by other articles:

				C. V. Maniu, J. B. Patel, D. G. Reuter, D. M. Meyer, W. D. Edwards, C. S. Rihal, and M. M. Redfield Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1652 - 1661. [Abstract] [Full Text] [PDF]

				D. J. Campbell Vasopeptidase Inhibition: A Double-Edged Sword? Hypertension, March 1, 2003; 41(3): 383 - 389. [Abstract] [Full Text] [PDF]